Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Brisson

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Pediatric Blood & Cancer|January 7, 2026
Outcomes Following Proton Radiation for Pediatric MeningiomasElizabeth Thompson, Daniel J Indelicato, Ryan J Brisson, et al.
Pediatric Blood & Cancer|September 26, 2024
Long-term outcomes following proton therapy for pediatric spinal low-grade gliomaRyan J Brisson, Daniel J Indelicato, Julie A Bradley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 10, 2024
Long-term outcomes following proton therapy for non-metastatic central nervous system germinoma in children and adolescentsRyan J Brisson, Daniel J Indelicato, Julie A Bradley, et al.
Pediatric Blood & Cancer|May 5, 2025
Proton Therapy for Locally Advanced Unresectable Ameloblastoma in a ChildAmanda Acevedo, Daniel J Indelicato, Ryan J Brisson, et al.
Cancer|September 21, 2021
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitorsCorey C Foster, Marcus A Couey, Sara E Kochanny, et al.
Radiation Oncology Journal|July 5, 2023
Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemicAlexandra N De Leo, Fantine Giap, Matthew M Culbert, et al.
Cancer|May 5, 2020
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO studyTanguy Y Seiwert, Sara Kochanny, Kevin Wood, et al.
International Journal of Radiation Oncology, Biology, Physics|April 21, 2020
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional OutcomesCorey C Foster, Tanguy Y Seiwert, Ellen MacCracken, et al.
Cancer|February 20, 2020
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinomaSara E Kochanny, Francis P Worden, Douglas R Adkins, et al.
Oral Oncology|May 1, 2018
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experienceCorey C Foster, James M Melotek, Ryan J Brisson, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Pediatric Blood & Cancer|January 7, 2026
Outcomes Following Proton Radiation for Pediatric MeningiomasElizabeth Thompson, Daniel J Indelicato, Ryan J Brisson, et al.
Pediatric Blood & Cancer|September 26, 2024
Long-term outcomes following proton therapy for pediatric spinal low-grade gliomaRyan J Brisson, Daniel J Indelicato, Julie A Bradley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 10, 2024
Long-term outcomes following proton therapy for non-metastatic central nervous system germinoma in children and adolescentsRyan J Brisson, Daniel J Indelicato, Julie A Bradley, et al.
Pediatric Blood & Cancer|May 5, 2025
Proton Therapy for Locally Advanced Unresectable Ameloblastoma in a ChildAmanda Acevedo, Daniel J Indelicato, Ryan J Brisson, et al.
Cancer|September 21, 2021
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitorsCorey C Foster, Marcus A Couey, Sara E Kochanny, et al.
Radiation Oncology Journal|July 5, 2023
Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemicAlexandra N De Leo, Fantine Giap, Matthew M Culbert, et al.
Cancer|May 5, 2020
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO studyTanguy Y Seiwert, Sara Kochanny, Kevin Wood, et al.
International Journal of Radiation Oncology, Biology, Physics|April 21, 2020
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional OutcomesCorey C Foster, Tanguy Y Seiwert, Ellen MacCracken, et al.
Cancer|February 20, 2020
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinomaSara E Kochanny, Francis P Worden, Douglas R Adkins, et al.
Oral Oncology|May 1, 2018
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experienceCorey C Foster, James M Melotek, Ryan J Brisson, et al.
Pageof 3